[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study (Q88645082)

From Wikidata

Jump to navigation Jump to search

scientific article published on 08 May 2018

Language	Label	Description	Also known as
English	[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study	scientific article published on 08 May 2018

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

phase II clinical trial

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Justin Ferdinandus

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Shahneen K Sandhu

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

author name string

Michael S Hofman

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

John Violet

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Rodney J Hicks

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Sue Ping Thang

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Tim Akhurst

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Amir Iravani

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Grace Kong

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Aravind Ravi Kumar

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Declan G Murphy

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Peter Eu

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Price Jackson

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Mark Scalzo

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Scott G Williams

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

publication date

8 May 2018

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

825-833

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Global cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased survival with enzalutamide in prostate cancer after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Alpha emitter radium-223 and survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

[¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Revisiting classification of pain from bone metastases as mild, moderate, or severe based on correlation with function and quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930198-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(18)30198-0

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29752180%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q88645082&oldid=1758305680"